Theresa LaVallee, PhD, is the Chief Development Officer of Coherus, and recently shepherded their drug toripalimab through a challenging approval process. She tells us what is next for the drug, the challenges facing medicine developers, and what keeps her enthusiastic about immuno-oncology.
Lead Editorial
